VISA, hetero-VISA and VRSA: The end of the vancomycin era?

Canadian Journal of Infectious Diseases

Volumn 13, Issue 5, 2002, Pages 282-284

  Conly, John M ^a   Johnston, B Lynn ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; METICILLIN; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; AUTOANALYSIS; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CLINICAL LABORATORY; CROSS RESISTANCE; HOSPITAL INFECTION; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRAIN DIFFERENCE; SURGICAL INFECTION;

EID: 0036761162     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/245109     Document Type: Article

References (38)

1. Lowey FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-32.
2. Clements MO, Foster SJ. Stress resistance in Staphylococcus aureus. Trends Microbiol 1997;11:458-62.
3. Spink WW, Ferris V. Quantitative action of penicillin inhibitor from penicillin-resistant strains of staphylococci. Science 1945;102:221.
4. Barber M. Methicillin-resistant staphylococci. J Clin Pathol 1961;14:385.
5. Brumfitt W, Hamilton-Miller JMT. Methicillin-resistant Staphylococcus aureus. N Engl J Med 1989;320:1188-96.
6. Panlilio AL, Culver DG, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-6.
7. Voss A, Milatovic D, Wallrauch-Schwarz C, et al. Methicillinresistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994;13:50-5.
8. Centers for Disease Control and Prevention. National nosocomial infections surveillance report - Data summary from October 1986-April 1996, issued May 1996. Am J Infect Control 1996;24:380-8.
9. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
10. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. NCCLS Approved Standard M7-A5. Wayne: National Committee for Laboratory Standards, 2000.
11. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3.
12. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7.
13. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-7.
14. Tenover FC, Mohammed MJ, Stelling J, O'Brien T, Williams R. Ability of laboratories to detect emerging antimicrobial resistance: Proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing. J Clin Microbiol 2001;39:241-50.
15. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7:327-32.
16. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997;46:626-8.
17. Centers for Disease control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois. MMWR Morb Mortal Wkly Rep 1999;48:1165-7.
18. Boyle-Vavra S, Carey RB, Daum RS. Development of lysostapin and vancomycin resistance in pre-GISA vancomycin-tolerant, methicillin-resistant Staphylococcus aureus isolate. J Antimicrob Chemother 2001;48:617-25.
19. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:765-6.
20. Rotun SS, McMath V, Schoonmaker DJ, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999;5:147-9.
21. Sieradzki K, Roberts R, Haber S, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus. N Engl J Med 1999;340:517-23.
22. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999. JAMA 2000;283:597-8.
23. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP. Vancomycin-resistant Staphylococcus aureus. Lancet 1998;351:602.
24. Ploy MC, Grelaud C, Martin C, deLumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998;351:1212.
25. Wong SS, Ng TK, Yam WC. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 2000;36:261-8.
26. Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999;353:1587-8.
27. Marchese A, Balistreri G, Tonoli E, Bebbia EA, Schito GC. Heterogeneous vancomycin-resistance in methicillin-resistant Staphylococcus aureus strains in a large Italian hospital. J Clin Microbiol 2000;38:866-9.
28. Geisel R, Schmitz FJ, Thomas L, et al. Emergence of heterogeneous intermediate vancomycin-resistance in Staphylococcus aureus isolates in the Dusseldorf area. J Antimicrob Chemother 1999;43:846-8.
29. Kim M-N, Hwang SH, Pyo Y-J, et al. Clonal spread of Scaphylococcus aureus heterogenously resistant to vancomycin in a university hospital in Korea. J Clin Microbiol 2002;30:1376-80.
30. Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999;29:760-7.
31. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3.
32. Bierbaum GI, Fuchs K, Lenz W, Szekat C, Gsahl H. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Microbiol Infect Dis 1999;18:691-6.
33. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:519-23.
34. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphyococcus aureus. N Engl J Med 1999;340:493-501.
35. Howe RA, Wooton M, Walsh TR, Bennet PM, MacGowan AP. Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus. J Antimicrob Chemother 1999;44:675-8.
36. Daum RS, Gupta S, Sabbagh R, Milewski WM. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: Isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis 1992;166:1066-72.
37. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997;179:2557-66.
38. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enteroccus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;93:195-8.